Mustang Bio, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Net Loss per Share (Tables)

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of Potentially Dilutive Securities


	For the three months ended March 31,
	2025	2024
Warrants ⁽¹⁾	7,052,001	56,254
Options	1,521	1,521
Class A preferred shares ⁽²⁾	333	333
Unvested restricted stock awards	1,195	1,285
Unvested restricted stock units	198	1,434
Total	7,055,248	60,827

(1)

For the three months ended March 31, 2025, total warrants exclude 1,492,807 pre-funded warrants issued in connection with the February 2025 Offering. For the three months ended March 31, 2024, total warrants exclude 19,280 pre-funded warrants issued in connection with the October 2023 Registered Direct Offering, respectively. The shares underlying the pre-funded warrants are included in the basic and diluted net loss per share for the three months ended March 31, 2025 and 2024.

(2)	Class A preferred shares are reflected on an as-if converted basis.